报告人：Dr. Dongfei Liu, University of Helsinki

报告时间：2017年11月10日9:45-10:30

报告地点：生科院二楼大会议室

邀请人：李子福教授

Abstract: A scalable approach that can generate narrowly size distributed nanomaterials with ultrahigh drug loading degree (mass fraction of therapeutics in nanomaterials), precise ratiometric control of co-loaded therapeutics, superior colloidal stability after administration, minimal off-target effects, as well as controlled drug release profiles at the site of action, is strongly desirable. Microfluidics is a versatile approach to encapsulate nanoparticles to form structured nanocomposites, such as core/shell nanoparticles. Taking advantage of the high loading degrees of porous silicon for both hydrophilic and hydrophobic therapeutics, multiple drugs with varied physicochemical properties were successfully loaded into the microfluidic assembled micro- and nano- composites with ratiometric control. By exploiting superfast (milliseconds) time intervals between sequential nanoprecipitation processes, an approach for high-throughput production of structured core/shell nanocomposites has been successfully developed. The extremely short time interval between the sequential nanoprecipitation processes, facilitated by the multiplexed microfluidic design, addresses the instability issues of nanocomposite cores without using any stabilizers. Beyond high throughput production rate (∼700 g/day on a single device), the generated core/shell nanocomposites harness the inherent ultrahigh drug loading degree and enhanced payload dissolution kinetics of drug nanocrystals and the controlled drug release from polymer-based nanoparticles. The advantages offered by microcapillary devices, such as good industrial scale-up validation, great batch-to-batch reproducibility, homogeneous size distribution, as well as high controllability of carriers’ physicochemical properties, can dramatically accelerate the translation of nanoparticulate drug delivery systems to the pharmaceutical industry.

Dr. Dongfei Liu currently is a Principal Investigator at the Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki (Finland). In June 2017, he has been selected as a fellow member of the Helsinki Institute of Life Science (HiLIFE). Dr. Liu is well-versed in a variety of fields, such as controlled drug delivery, nanomedicine, microfluidics, biomaterials, and spinal cord injury therapy. Primarily, he is interested in engineering drug delivery systems featured with ultrahigh mass fraction of therapeutics and precisely controlled drug release profiles. For example, Dr. Liu has fabricated an optimal nano-in-nano vector, which successfully merged the favorable characteristics of polymer nanoparticles (e.g., controlled release) and drug nanocrystals (e.g., high mass fraction of therapeutics). Since 2009, he has been the author of ca. 40 peer-reviewed articles published in leading scientific journals (e.g., Advanced Materials, Nano Letters, and Advanced Functional Materials). Despite his specific field of research, Dr. Liu’s work has been well cited (ca. 600 citations; Scopus h-index = 15). From 2016, he has received several competitive grants from agencies such as the Academy of Finland (2017-2020), HiLIFE grant (2017-2020), the University of Helsinki Research Funds (2017-2019), and the Jane and Aatos Erkko Foundation (2016–2018). Dr. Liu has also been granted a number of prestigious awards, such as the Young Researcher Award from the Faculty of Pharmacy in 2017, the Best Doctoral Dissertation of the University of Helsinki in 2014, and the Outstanding Self-Financed Students from the China Scholarship Council (2013). Furthermore, Dr. Liu has served as a consulting editor of Dovepress since 2015.

欢迎广大师生积极参加！